Elafibranor for primary biliary cholangitis
2026
Read Elafibranor for primary biliary cholangitis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13487671.txt.
Description
Wong and the editors of Australian Prescriber prepared a short drug comment in 2026 on elafibranor, sold as Iqirvo. The drug treats primary biliary cholangitis, a slow liver disease that harms the small bile ducts. It is meant for adults who gain too little from the usual first drug, ursodeoxycholic acid, or who cannot take that drug at all.
Elafibranor turns on two cell switches, called PPAR-alpha and PPAR-delta, that help control bile acids, swelling, and scar growth in the liver. In the ELATIVE trial, about half of the treated patients met the blood test goal at one year. Very few on placebo did so, and gains showed within four weeks. Common side effects were gut pain, loose stools, and nausea, mostly mild in grade.
Catalog record
| YEAR | 2026 |
|---|---|
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |